Arctigenin Isolated from Arctium Lappa L. Inhibits IgE Production
Monday, March 7, 2016
South Exhibit Hall H (Convention Center)
Changda Liu, PhD, Kamal D. Srivastava, PhD, Nan Yang, PhD, Madisyn A Primas, Renna Bushko, Kyle Chin, Matthew Batnick, Xiu-Min Li, MD,MS
Rationale: Medicinal herbs provide relief to a large percentage of the world population suffering from inflammatory diseases and a major resource for new drug development. The medicinal herb Arctium lappa L. is been widely used to treat inflammation. The aim of this study was to identify the bioactive compound in this herb that inhibits IgE production.

Methods: Liquid-liquid extraction, silica gel, and Sephadex LH20 column chromatographic methods were used for isolation and purification of compounds. IgE inhibitory effects on human B cells (U266 human myeloma cells), peripheral blood mononuclear cells (PBMCs) from allergic patients, and peanut sensitized and challenged murine asthma model was assessed.

Results: The compounds isolated and purified (purity is>95%) from Arctium lappa L.were identified as arctiin and arctigenin with dose-dependently and significantly inhibition of U266 cells IgE production (as low as 5μg/mL for arctiin and 2. 5μg/mL for arctigenin) without any sign of cytotoxicity. Arctiin and arctigenin (as low as 1μg/mL) also non-toxically abolished IL-4 and anti-CD40 stimulated IgE production by PBMCs from food allergic patients. Arctigenin (20mg/kg) decreased score of anaphylactic reactions, blocked body temperature decrease, and reduced peanut-specific IgE levels on peanut allergic mouse model.

Conclusions: Both arctiin and arctigenin inhibited IgE production in human B cell line and food allergic patient PBMCs. Arctigenin blocked anaphylactic reactions in a murine model of peanut allergy. Arctigenin may have potential for treatment of IgE associated inflammatory diseases, which requires further investigation.